ErVimmune is a preclinical biotechnology spin-off from the Centre Léon Bérard focused on creating next-generation cancer vaccines and cell therapies for tumors that resist current immunotherapies. Its platform identifies unconventional tumor epitopes originating from human endogenous retroviruses (HERVs) to spark robust anti-tumor immune responses. The company’s lead candidate, ErVac01, is being advanced toward clinical evaluation in triple-negative breast cancer and ovarian cancer. Beyond ErVac01, ErVimmune is building a pipeline of therapeutic candidates aimed at additional oncology indications driven by novel HERV-derived antigens. The business recently strengthened its leadership by appointing Eric Halioua as executive chairman to steer it through upcoming clinical milestones. Financially, ErVimmune secured €17 million in the first close of its Series A round, providing runway to progress its lead program and expand its pipeline.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026